Posaconazole is a triazole antifungal drug marketed in the United States by Schering-Plough under the trade name Noxafil. Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.
Related Products:
Posaconazole intermediate(149809-43-8; 184177-83-1; 175712-02-4)